Join The Discussion

 

Trademark closes on 63-acre Waterside site in Fort Worth

Construction begins Oct. 20 on the development, to be anchored by a Whole Foods Market.

read more >

Two Fort Worth council members propose temporary single-family moratorium around TCU

The moratorium would apply to new permits for single-family homes around TCU, and give the city time to figure out what to do with a controversial proposed overlay in several neighborhoods around the university.

read more >

Fresh Ebola fears hit airline stocks

DALLAS (AP) — News that a nurse diagnosed with Ebola flew on a plane full of passengers raised fear among airline investors that the scare over the virus could cause travelers to avoid flying.

read more >

Landscape architect behind several TCU landmarks acquired

The Dallas design firm behind several Texas Christian University projects, as well as Globe Life Park in Arlington and AT&T Stadium, has been acquired by Rvi Planning + Landscape Architecture.

read more >

Fort Worth launching Stockyards design task force

The task force, to be chaired by the Fort Worth architect Eric Hahnfeld, would be responsible for confirming the boundaries of the city's planned Stockyards design district and reviewing the work of a consultant.

read more >

Galderma gains distribution rights in U.S., Canada

Nestle S.A., Switzerland, a shareholder of Fort Worth-based Galderma Laboratories LP, has entered into an agreement with Valeant Pharmaceuticals International Inc. to become the distributor of several products in aesthetic dermatology.
Galderma will gain full rights to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the United States and Canada.
Restylane, Perlane and Emervel are manufactured by Galderma and sold by its subsidiaries globally, except in the U.S. and Canada, where Valeant holds the distribution rights under terms of a pre-existing agreement with Medicis, which was acquired by Valeant in 2012. Through this transaction, Galderma will be able to further develop and supply these brands globally.


Galderma is acquiring Sculptra, owned by Valeant, and will commercialize it in the U.S. and Canada and select other markets around the world.
Dysport (branded Azzalure in Europe) is marketed by Galderma for aesthetic dermatology indications in many markets around the world. Valeant holds the distribution rights for the aesthetic dermatology indications under a similar agreement with Ipsen. The transaction will allow Galderma to distribute Dysport in the U.S. and Canada.


“The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics market. This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service and consumer awareness,” said Humberto C. Antunes, president and chief executive officer of Galderma worldwide.
This transaction is subject to regulatory clearance and other customary closing conditions. Credit Suisse acted as financial advisers, and Debevoise and Plimpton as legal advisers to Galderma.
In February 2014, Nestle announced that it had entered into an agreement with L’Oreal S.A. under which it will acquire the remaining 50 percent of Galderma owned by L’Oreal. The transaction between Nestle and Valeant is subject to regulatory clearance and certain other conditions, and is expected to close in July.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Ebola
How worried are you about Ebola spreading?